Glucocorticoids suppress early lung inflammation and impair control of SARS-CoV-2 in non-human primates

TL;DR

Glucocorticoids reduce lung inflammation in SARS-CoV-2 infected non-human primates but may hinder viral clearance and immune responses.

Contribution

This study identifies specific immune cell types affected by glucocorticoids during SARS-CoV-2 infection.

Findings

Glucocorticoids reduced lung inflammation in infected non-human primates.

Glucocorticoids increased SARS-CoV-2 viral titers in the lower airways and lymph nodes.

Glucocorticoids suppressed specific immune cell responses in the airways.

Abstract

In severe cases of COVID-19, glucocorticoid treatment improves clinical outcomes. However, in non-hospitalized patients, glucocorticoids have limited benefit and may impair viral clearance. Here, we used the rhesus macaque model of acute SARS-CoV-2 infection to investigate the impact of glucocorticoids on host responses and viral control in a setting of mild disease. Rhesus macaques were pre-treated with intravenous methylprednisolone for 5 days prior to SARS-CoV-2 (Delta) infection and maintained on a daily oral prednisolone until necropsy at day 13 post infection. Glucocorticoid (GC) treatment decreased local lung inflammation measured with 18FDG-PET/CT imaging. GC treated animals also had evidence of elevated SARS-CoV-2 viral titers in the lower airways and pulmonary draining lymph nodes. Glucocorticoid treatment blunted plasmacytoid dendritic cell (pDC), eosinophil, gamma delta T cell and early SARS-CoV-2 specific CD8 T cell responses in the airways. These data reveal the cell types that are directly impacted by immunosuppression with glucocorticoids and provide insights into the mechanism of delayed viral clearance observed with glucocorticoid administration during SARS-CoV-2 infection.

Figures